Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senate Finance Committee Seeks Review Of Manufacturer Investigations By DOJ, HHS

This article was originally published in The Pink Sheet Daily

Executive Summary

Sen. Grassley requests briefings on the “scope and subject matter of all pending drug company investigations.” He is concerned that settlements like the Pfizer Neurontin deal are viewed as a cost of doing business.
Advertisement

Related Content

“Whistleblower” Suits Should Be Encouraged By Rx Manufacturers, Sen. Grassley Says
“Whistleblower” Suits Should Be Encouraged By Rx Manufacturers, Sen. Grassley Says
Pfizer Will Monitor Off-Label Drug Use And Report To IG Under Neurontin Settlement
Pfizer Will Monitor Off-Label Drug Use And Report To IG Under Neurontin Settlement
Neurontin Settlement Of $430 Mil. Is High For Off-Label Case, Low For Pfizer
Senate Finance Committee Inquires Into Manufacturer Medicaid Best Price Calculations

Topics

Advertisement
UsernamePublicRestriction

Register

PS059421

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel